ARTICLE | Company News
MedImmune, VasGene antibody deal
September 9, 2005 1:47 AM UTC
MEDI and VasGene (Los Angeles, Calif.) partnered to develop VasGene's preclinical MAbs targeting Eph receptor B4 (EphB4) and its ligand, Ephrin B2 (Efnb2), to treat cancer. MEDI is responsible for cli...